Anticholinergic Drug Class List

Drugs in Drug Class: Anticholinergic

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan Ireland Ltd	YUPELRI	revefenacin	SOLUTION;INHALATION	210598-001	Nov 9, 2018		RX	Yes	Yes			Y
Mylan Ireland Ltd	YUPELRI	revefenacin	SOLUTION;INHALATION	210598-001	Nov 9, 2018		RX	Yes	Yes
Mylan Ireland Ltd	YUPELRI	revefenacin	SOLUTION;INHALATION	210598-001	Nov 9, 2018		RX	Yes	Yes				Y
Mylan Ireland Ltd	YUPELRI	revefenacin	SOLUTION;INHALATION	210598-001	Nov 9, 2018		RX	Yes	Yes
Mylan Ireland Ltd	YUPELRI	revefenacin	SOLUTION;INHALATION	210598-001	Nov 9, 2018		RX	Yes	Yes
Mylan Ireland Ltd	YUPELRI	revefenacin	SOLUTION;INHALATION	210598-001	Nov 9, 2018		RX	Yes	Yes

Anticholinergic Drugs: Market Dynamics and Patent Landscape

Last updated: April 24, 2026

What defines the anticholinergic market and where does value sit?

Anticholinergics are a broad therapeutic class that includes muscarinic receptor antagonists (most clinically important) and related compounds used across chronic and acute indications. The market is dominated by inhaled and oral therapies for chronic obstructive pulmonary disease (COPD), overactive bladder (OAB), and gastrointestinal (GI) indications, with additional usage in ophthalmology and neurologic care.

Value is concentrated where (1) dosing is chronic, (2) delivery systems support adherence, and (3) patents are still active or protected by follow-on IP (reformulation, combination products, prodrugs). Competitive dynamics vary by indication:

• OAB: Long-cycle demand with premium pricing for differentiated formulations and branded entrants. Generic erosion is common once brand exclusivity lapses.
• COPD (inhaled antimuscarinics): MoA is stable but competition is intense among long-acting muscarinic antagonists (LAMAs) and LAMA/LABA fixed-dose combinations.
• GI antispasmodics: Higher generic penetration, with branded products usually maintained through differentiation (dose forms, patient subsets) and controlled-release strategies.
• Ophthalmic: Smaller volumes but higher net pricing; patent cliffs can create rapid share shifts.

Where are the major anticholinergic patent “hot spots”?

Across anticholinergic drugs, the patent landscape clusters around four repeatable themes:

1. New muscarinic antagonist molecules (primary composition of matter).
2. Long-acting delivery (controlled release, depot formulations, dry powder inhalers, transdermal systems).
3. Combination products (fixed-dose LAMA/LABA or antimuscarinic plus other respiratory agents).
4. Method-of-use claims (dosing regimens, specific patient subgroups, device-assisted regimens).

This matters because the dominant market segments typically rely on inhalation and controlled-release oral formats. Those formats create multiple layers of patentable improvements even when core compound coverage expires.

What is the current market dynamic by leading anticholinergic revenue drivers?

The anticholinergic market behaves like a mix of three submarkets:

• Chronic respiratory (COPD/LAMA): Brands remain strong where inhaler devices support adherence and where combination products (LAMA/LABA) extend lifecycle.
• Chronic urology (OAB): Brand strength is tied to tolerability differences (dry mouth rate) and adherence via dosing convenience.
• Acute or intermittent use (GI spasms, some neurologic uses): Faster generic substitution once substitution conditions are met.

A consistent pattern exists: patent-protected inhalation or extended-release oral products delay price erosion, while immediate-release antispasmodics usually face earlier and deeper generic penetration.

How does the anticholinergic patent landscape structure exclusivity in practice?

Patent coverage for anticholinergics often extends beyond composition-of-matter with:

• Drug product patents: controlled-release coatings, granulation methods, inhaler/device formulations, and stable polymorph claims.
• Combination patents: fixed-dose combination ratios, patient selection claims, and dosing schedules.
• Regulatory exclusivity: where applicable, data exclusivity and market exclusivity periods can create a buffer even when earlier patents expire.

Because anticholinergics are mature, portfolio-level protection frequently relies on follow-on IP. That shifts risk toward products with:

• early composition expiry,
• limited manufacturing or formulation IP,
• weak method-of-use coverage.

Which anticholinergic molecules anchor major modern IP portfolios?

The modern anticholinergic landscape for large-volume markets is anchored by:

Respiratory (LAMAs and LAMA combinations)

Key muscarinic antagonists with significant lifecycle activity:

• Tiotropium (historically dominant; multiple generations of formulations)
• Aclidinium
• Glycopyrronium
• Umeclidinium
• Revefenacin (notable in nebulized LAMA use cases)

OAB / urology

Common muscarinic antagonists and related anticholinergic urology agents:

• Oxybutynin (multiple formulations; transdermal and extended release)
• Tolterodine
• Solifenacin
• Darifenacin
• Fesoterodine
• Trospium

GI antispasmodics

Typical agents with generic pressure:

• Dicyclomine
• Hyoscine (scopolamine) derivatives
• Drotaverine (where used)
• Propantheline (These often have earlier generic substitution; IP focus is frequently on formulation.)

Ophthalmic anticholinergics

• Atropine and related mydriatic/antisecretory agents Market dynamics hinge on formulation patents and indication-specific exclusivity.

Where are patent cliffs most likely to reshape share?

Share shifts in anticholinergics follow a repeatable pattern:

• When a top-selling inhaled or extended-release oral product loses its last meaningful formulation/device patent, follow-on generics or “authorized” competitors gain room to price.
• When combination products face patent expiry, competitors that can offer either:
  • an equivalent combination, or
  • individually generic components, can repackage advantage rapidly.

Practically, portfolio risk concentrates at “last-to-expire” points across multiple patent families: compound + device + formulation + combination.

What does the patent landscape imply for R&D strategy?

Anticholinergic R&D that aims to win commercially faces a narrowing set of viable differentiation levers:

1. Delivery differentiation is more defensible than minor molecule changes in a mature MoA area.
2. Adherence-driven dosing (once-daily inhalers, extended-release tablets, transdermal convenience) is where lifecycle extension is most common.
3. Patient subgroup claims can preserve value for longer if trial designs support those labels.
4. Combination strategy is usually the fastest path to sales scale if you can enter the inhalation or chronic urology treatment algorithm.

The investment thesis in anticholinergics is less about finding a new mechanism and more about building a defendable IP moat around dosing convenience, tolerability, and device compatibility.

How are regulatory and competitive cycles affecting anticholinergic patent value?

Anticholinergics are frequently evaluated within crowded formularies and payer preference structures. That changes the patent value equation:

• Payers push to lowest WAC where generic equivalents appear.
• Branded products must maintain a value proposition tied to:
  • clinical tolerability,
  • dosing adherence,
  • reduced switching.

As patent cliffs approach, the most defensible strategy is:

• lock in combination uptake where coverage continues,
• secure formulation/device follow-on IP,
• maintain label differentiation for high-value subgroups.

What are the practical deal and IP signals to track in anticholinergics?

For business diligence, the most actionable signals are:

• “Last-to-expire” mapping by product line: identify the final family for the specific marketed dosage form and regimen.
• Device/formulation patent coverage strength: nebulizers, inhalers, extended-release coatings, and polymorph claims.
• Combination IP breadth: whether claims cover ratios and dosing schedules or only general combination concepts.
• Generic launch timing: competitor filings often track the expected expiry window and can accelerate price erosion.

How does patent strategy differ across respiratory vs urology anticholinergics?

Respiratory anticholinergics:

• rely heavily on inhaler/device improvements and combination products,
• see intense competitive response when combination coverage ends.

Urology anticholinergics:

• rely more on formulation and dosing convenience to manage tolerability,
• experience generic substitution but retain value when patients are stabilized on a particular branded formulation.

GI antispasmodics:

• are typically exposed earlier to broad generic penetration,
• lifecycle depends on product differentiation rather than durable composition ownership.

Key Takeaways

• Anticholinergic drug value concentrates in chronic respiratory (LAMA and LAMA/LABA) and chronic urology (OAB), where lifecycle strategies rely on formulation, delivery, and combination IP.
• Patent cliffs tend to trigger rapid share shifts when the last-to-expire device/formulation/combination patents lapse, especially in inhaled and fixed-dose products.
• Winning R&D and investment strategies in this MoA class focus on defendable dosing convenience, tolerability differentiation, and device-compatible IP, not solely on new molecular entities.

FAQs

1) Which patent areas matter most for anticholinergic brands after compound expiry?

Formulation/device and combination patents usually determine whether a brand retains pricing power after composition-of-matter coverage ends.

2) Do anticholinergics face faster generic erosion in all indications?

No. GI antispasmodics generally erode faster than inhaled COPD and OAB where delivery and tolerability differentiation can slow switching.

3) Why are combination products central to anticholinergic lifecycle management?

They extend exclusivity by creating a new marketed regimen and can provide additional claim coverage around ratios, dosing schedules, and specific use-cases.

4) What diligence step most directly predicts near-term price pressure?

Mapping the last-to-expire patent family for the marketed dosage form and regimen, including device and formulation.

5) What R&D differentiation is most defensible for a new anticholinergic entrant?

Differentiation tied to delivery system performance, extended-release behavior, and adherence-linked dosing that supports label differentiation.

---

References

[1] Bloomberg. “Drug patent” and “pipeline” coverage and public patent monitoring content (editorial databases). Bloomberg data products accessed via licensed services.